ABC of ADC: how a new generation of this cancer drug goes the extra mile
06 January 2020 - 14:25
Frankfurt — A class of treatments known as antibody-drug conjugates (ADC), which combine cancer-tracking proteins with powerful cell toxins, are getting a fresh start as dozens of drugmakers test a record number of new compounds in people.
Nearly 20 years after the first ADC, Pfizer’s Mylotarg, was approved, developers say they are now getting a handle on the technology that was long seen as an elegant concept, but one that presented many clinical challenges...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.